ost cellular processes are controlled by the regulation of key proteins. Autoinhibition and post-translational modification (PTM) are two common regulatory mechanisms. Many well-known regulatory proteins are autoinhibited 1 , requiring various mechanisms to release the autoinhibitory interaction. A variety of PTMs can trigger major changes in protein activity or location. Autoinhibition and PTM are both frequently involved in the regulation of the same protein 1, 2 . Members of the formin family of actin assembly factors are key players in a diverse range of cellular functions, including cytokinesis, cell motility, phagocytosis and organelle dynamics. Several of the 15 mammalian formins are known or predicted to be autoinhibited [3] [4] [5] , with 10 mammalian formins 6,7 containing two autoregulatory sequences: the amino (N)-terminal diaphanous inhibitory domain (DID) and the carboxyl (C)-terminal diaphanous autoregulatory domain (DAD). The autoinhibitory mechanism of one formin, mDia1, has been described in detail 8 . Binding of GTP-charged RhoA to the GTPase-binding domain of mDia1 activates the formin by disrupting the interaction between DID and DAD 8, 9 . Atomic structures have been solved for DID alone and the DID-DAD complex, and a single point mutation in the DAD-binding site in DID has been shown to eliminate autoinhibition 9, 10 . INF2 is a mammalian formin that contains DID and DAD sequences. Biochemically, INF2 has multiple effects on actin 11, 12 , as well as having both direct and indirect effects on microtubules [13] [14] [15] [16] . In cells, INF2-mediated actin polymerization plays roles in mitochondrial fission, calcium transfer from the endoplasmic reticulum to the mitochondria, vesicle trafficking and Golgi structure [17] [18] [19] [20] [21] . Dominant missense mutations in INF2 are linked to two diseases, focal segmental glomerulosclerosis (FSGS) 22 and CharcotMarie-Tooth disease (CMTD) 23 . Interestingly, all of the more than 35 disease-linked mutations map to the DID, suggesting regulatory effects. Few disease-associated mutations, however, are found in its DAD-binding site. Three pieces of evidence have suggested that INF2 does not engage in canonical autoinhibition. First, the DID-DAD interaction of INF2 is more than tenfold weaker than that of mDia1 (refs. 11,24,25 
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is inhibited through interaction between DID and DAD in cells, but that this interaction is insufficient to inhibit purified INF2. One explanation could be that a cellular factor facilitates the interaction between DID and DAD. In this study, we identified such a factor.
Identification of an INF2 inhibitory protein.
Two possible mechanisms by which an inhibitor could enhance the interaction between DID and DAD are direct binding or PTM (Fig. 1e) . We used a biochemical approach to identify either mechanism, mixing chromatographic fractions from mouse brain with purified INF2-FL, then assaying the rate of actin polymerization. We made two assumptions: (1) the inhibitor would be cytosolic, because both INF2-CAAX and INF2-nonCAAX are inhibited in cells; and (2) the inhibitor would be abundant, because even cells that strongly overexpress INF2-WT do not display aberrant actin polymerization ( Supplementary Fig. 1b,c) .
We used five chromatographic steps in the purification process (Fig. 1f) , assessing INF2-FL inhibition through a pyreneactin polymerization assay (Fig. 1g,h, Supplementary Fig. 2a-c) . In the final step, inhibitory activity eluted with the major protein peak (Fig. 1i) . We refer to this fraction as 'brain inhibitory fraction' (BIF). Importantly, BIF does not inhibit actin polymerization by INF2-FFC (Fig. 1h,i ) or mDia1-FFC ( Supplementary Fig. 2d ), demonstrating that it is not acting as a general inhibitor of actin polymerization. The inability of BIF to inhibit INF2-FFC also demonstrates that DID is required for inhibition. In addition, BIF does not cause significant INF2 proteolysis ( Supplementary Fig. 2e ), suggesting that the inhibitor is not a protease. Furthermore, BIF loses all activity after being subjected to boiling ( Supplementary Fig. 2f) . These experiments reveal a cytosolic protein inhibitor of INF2 that requires the DID domain of INF2 for inhibition.
The CAP-actin complex is an INF2 inhibitor. Five visible bands were identified in the BIF by SDS-PAGE and silver staining (Fig. 1j) as follows: band 1, exportin1/7; band 2, heat-shock cognate 71 kDa protein (HSP7C) and vacuolar ATPase subunit A (VATA); band 3, cyclase-associated proteins 1 (CAP1) and 2 (CAP2) and vacuolar ATPase subunit B2 (VATB2); band 4, CAP2, CAP1 and VATA; and band 5, actin (Supplementary Table 1 ). We immunodepleted individual proteins from BIF and tested the ability of the proteins in these depleted fractions to inhibit INF2-FL. Depletion of CAP2 eliminates INF2 inhibition (Fig. 2a,b) , whereas the depletion of VATA, VATB2 or HSP7C has no effect ( Supplementary Fig. 3 ). Available antibodies against CAP1 and exportin proved unsuitable for depletion.
These results suggest that CAP2 is required for INF2 inhibition by BIF. As additional inhibitory peaks were identified in the first two purification steps ( Supplementary Fig. 2a,b) , we used western blotting to determine whether CAP1 or CAP2 was present in these fractions. CAP1 and CAP2 were both detected in inhibitory fractions by using anion-exchange chromatography ( Supplementary Fig. 2a ) and size-exclusion chromatography ( Supplementary Fig. 2b ). These results suggest that endogenous CAP complexes are heterogeneous in size, but that all CAP-containing peaks can inhibit INF2. 0 200 400 600 800  1,000  0  1,000 2,000 3,000 4,000 5,000 1,200 IgGH I P -p e l l e t I P -s u p e r n a t a n t I P -p e l l e t I P -s u p e r n a t a n t Supplementary Fig. 2a )) was incubated with either a non-specific (NS) antibody or an anti-CAP2 antibody, followed by precipitation using protein A beads. CAP2 protein in the input, supernatant and pellet was detected by western blotting. IgGH, antibody heavy chain from the IP. The experiment was performed once. IB, immunoblot. b, Pyrene-actin polymerization assay (2 µM actin monomer, 5% pyrene) testing inhibitory activity of immune-depleted supernatants on 20 nM INF2-FL. IP/NS-Sup, supernatant from the immunodepletion with the non-specific antibody; IP/CAP2-Sup, supernatant from the immunodepletion with the anti-CAP2 antibody. The experiment was performed once in triplicate. c, Coomassie-stained SDS-PAGE of coexpressed CAP1-GFP and CAP2-GFP purified from HEK293 cells. The experiment was performed two times with similar results. d,e, Pyrene-actin polymerization assay (2 µM actin monomer, 5% pyrene) testing the effect of coexpressed CAP1 and CAP2 (5 μM, untagged) on 20 nM INF2-FL (d) or 20 nM INF2-FFC (e). The experiment was performed five times with similar results. f, Comparison of inhibitory activities of recombinant CAP2 and CAP in BIF on INF2-FL (20 nM) in pyrene-actin polymerization assays. The assembly rate of actin alone and with INF2-FL is also shown. CAP concentration in BIF was determined as described in the Methods. The experiment was performed five times with similar results for recombinant CAP2, and once for BIF.
To further test CAP as an INF2 inhibitor, we purified recombinant human CAP-containing C-terminal GFP and Strep-tag II (CAP-GFP)-from HEK293 cells. We purified three versions of CAP: CAP1, CAP2, and coexpressed CAP1 and CAP2. When analysed by SDS-PAGE, all CAP-GFP fusion proteins contained two additional bands: untagged CAP and actin (Fig. 2c, Supplementary  Fig. 4a ). The mean molar ratio of untagged CAP to CAP-GFP was 0.16 in all cases, whereas the mean actin:CAP-GFP ratio was 0.88 (Table 1) . Quantification of the protein bands in the BIF revealed an actin:CAP ratio of around 1:1 (Table 1) . CAP elutes as a high-mass particle by gel filtration (Supplementary Fig. 4b ), and CAP-GFP sediments as a 14.5 S particle by vAUC, with a calculated molecular mass of 726 kDa ( Supplementary Fig. 4c ). Considering past studies that have shown CAP hexamerization 26, 27 , we interpret our purified CAP-GFP to be a hexamer with a 5:1 ratio of CAP-GFP to untagged CAP (likely endogenous HEK293 CAP), and an actin monomer bound to a mean of five CAP subunits.
Recombinant CAP-actin inhibits actin polymerization by INF2-FL (Fig. 2d) but not by INF2-FFC (Fig. 2e, Supplementary  Fig. 4f ). However, the inhibitory potency of recombinant CAPactin is substantially lower than that of BIF (Fig. 2f) . The halfmaximum inhibitory concentration (IC 50 ) for CAP in BIF is 69 nM, whereas recombinant CAP does not reach its IC 50 at the maximum concentration tested. We obtained similar results for recombinant CAP1-actin and CAP2-actin, both with and without GFP ( Supplementary Fig. 4d ). In the absence of INF2, CAP-actin has little effect on actin polymerization at the highest concentration tested ( Supplementary Fig. 4e ). These results suggest that CAP is a component of the INF2 inhibitory factor, although recombinant CAP does not inhibit maximally.
Actin is an important component of CAP-mediated INF2 inhibition. We reasoned that the difference in inhibition between recombinant CAP and BIF might be due to differences in the bound actin. Therefore, we attempted to exchange actin in our recombinant CAP-actin (hereafter called CAP-293A) with other types of actin. We first tested actin exchange on CAP by mixing immobilized CAP-293A with fluorescently labelled actin (tetramethylrhodamine-succinimide; TMR-actin) and monitoring bead-bound fluorescence ( Supplementary Fig. 5a ). An appreciable level of fluorescent actin was associated with the CAP-293A-bound beads, but not with control GFP beads ( Supplementary Fig. 5b ). The ratio of actin:CAP is not changed significantly compared with the mockexchanged CAP (Supplementary Fig. 5b ). These results show that actin monomers can exchange onto CAP.
We exchanged CAP with total brain actin (BA; Supplementary  Fig. 5c ). CAP-BA displays significantly more INF2 inhibition (IC 50 = 54 nM) than CAP-293A (Fig. 3a,b) , but does not inhibit INF2-FFC (Fig. 3c) . We next exchanged CAP with two types of skeletal muscle actin, from chicken (CSKA) or rabbit (RSKA). Interestingly, CAP-CSKA inhibits INF2-FL with an IC 50 close to that of CAP-BA (IC 50 = 254 nM; Fig. 3d,e) , but does not inhibit INF2-FFC ( Supplementary Fig. 4f ). By contrast, CAP-RSKA is a poor INF2 inhibitor, similar to CAP-293A (Fig. 3d,e) . These results show that the source of the CAP-bound actin significantly affects INF2 inhibition.
We next investigated whether INF2 binds to CAP-actin directly. First, we used a cellular co-immunoprecipitation (co-IP) approach, transfecting U2OS cells with GFP-INF2, then conducting anti-GFP IP and probing for CAP. CAP2 coprecipitates with GFP-INF2-FL but neither with GFP-INF2-FFC nor with INF2-FL-A149D (Fig. 3f) . We also analysed the INF2-CAP interaction using purified proteins, by incubating immobilized GFP-INF2-FL or GFP-INF2-FFC with CAP-CSKA in solution, then analysing the bead-associated CAP. CAP associates with INF2-FL to a greater extent than INF2-FFC (Fig. 3g,h ). These results suggest that CAP-actin inhibits INF2 by direct interaction. Furthermore, CAP-CSKA binds to INF2 better than CAP-293A (Fig. 3i) , consistent with their different inhibitory potencies. These results suggest that the interaction between DID and DAD enhances INF2 binding to CAP-actin, and that INF2-CAP interaction requires a specific type of actin.
Profilin is an abundant cytosolic actin-binding protein, and a substantial proportion of cytosolic actin monomer is profilinbound 28 . In addition, profilin binds CAP 29 . We tested the effect of profilin on INF2 inhibition by CAP-CSKA. Through a pyreneactin polymerization assay, we found that CAP-CSKA still potently inhibits INF2 in the presence of profilin ( Supplementary Fig. 5d ), even though profilin slows overall actin polymerization significantly. We also conducted total internal reflection (TIRF) microscopy assays of INF2-mediated actin polymerization in the presence of profilin to distinguish between effects on actin nucleation and elongation. INF2 significantly increases nucleation rate (Fig. 4a,b) , and increases the filament elongation rate approximately twofold (Fig. 4c) . CAP-CSKA eliminates the INF2 effect on nucleation, but does not substantially affect nucleation of profilin and actin alone (Fig. 4a,b) . CAP-CSKA has little effect on the profilin-actin elongation rate, but inhibits profilin-actin elongation in the presence of INF2 (Fig. 4c) . These results show that INF2 inhibition by CAPactin can occur in the presence of profilin.
Actin acetylation increases INF2 inhibition by CAP-actin. Next, we probed the mechanism behind the differing inhibitory potencies of CAP-CSKA and CAP-RSKA. Actin is highly conserved. In particular, CSKA and RSKA are 100% identical in amino acid sequence. One possible explanation for the inhibitory variation between CSKA and RSKA is differential actin PTM. We identified acetylation of several actin lysine residues for CAP-CSKA, including K50, K61, K326 and K328, using mass spectrometry analysis (Supplementary Table 2 ). We therefore tested whether lysine acetylation of actin was required for INF2 inhibition.
First, we attempted to deacetylate CAP-CSKA. Histone deacetylase 6 (HDAC6) is a major cytosolic lysine deacetylase 30 . We expressed and purified Flag-tagged HDAC6 ( Supplementary  Fig. 5e ), which has substantial deacetylase activity on brain tubulin ( Supplementary Fig. 5f ). In pyrene-actin polymerization assays, HDAC6 strongly reduces CAP-CSKA inhibition of INF2, while minimally affecting the polymerization of actin alone or in the presence of INF2 (Fig. 5a) . Pretreatment of HDAC6 with trichostatin A (TSA), an HDAC inhibitor, abolishes its effect on CAP-CSKA (Fig. 5a ). The concentration curves of CAP-CSKA treated with HDAC6 alone versus HDAC6 and TSA show a marked difference in inhibitory activities (Fig. 5b) , suggesting that lysine acetylation of actin is necessary for CAP-actin inhibition of INF2.
As a second approach to test the effect of HDAC6, we purified CAP-actin from 293 cells in which HDAC6 activity was Calculated from densitometry of Coomassie-stained SDS-PAGE. CAP1, CAP2, and CAP1 and CAP2 are purified GFP-fusion proteins from HEK293 cells. BIF, purified proteins from BIF. NA, not applicable. a CAP-GFP (for CAP1, CAP2, and CAP1&2) or CAP (BIF) set to 100%. n = number of independent protein preparations analysed. inhibited. Cells were treated either with dimethylsulfoxide (DMSO) or with the HDAC6-specific inhibitor tubastatin A (TubA), before cell extraction and protein purification. Two tests indicated the effectiveness of TubA treatment. First, acetylated tubulin in cell extracts increased substantially ( Supplementary Fig. 5g ). Second, the amount of acetylated lysine detected on actin in purified CAP-293A increased ( Supplementary Fig. 5h ). TubA-treated CAP-293A (CAP-293A-T) inhibits INF2-mediated actin polymerization with an IC 50 of 263 nM, which is substantially more potent than the DMSO-treated sample (CAP-293A-D; Fig. 5c ). These results suggest that (1) HDAC6 deacetylates actin in cells and (2) increased actin acetylation increases CAP-actin inhibitory potency. We used the higher inhibitory potency of CAP-293A-T versus CAP-293A-D to analyse the direct interaction between INF2 and CAP-actin in more detail. Analysis by vAUC showed that CAP-293A-T causes a portion of GFP-INF2-FL to shift to a 12.6 S species ( Fig. 5d , red curve), which is greater than that of the untagged CAP-293A-T complex (11.2 S, grey curve), suggesting INF2 binding to the hexameric CAP complex. CAP-293A-D does not produce this magnitude of shift in GFP-INF2 (Fig. 5d , blue curve), suggesting a lower affinity. In addition, CAP-293A-T causes no shift of GFP-INF2-FFC ( Supplementary Fig. 5i ), suggesting that the DID is required for the high-affinity interaction.
We also used fluorescence polarization of fluorescently Table 3 ). These results suggest that the increase in CAP-actin inhibitory potency might be linked to acetylation of Lys 50, Lys 68, Lys 215 and/or Lys 315.
The ability of HDAC6 to abolish CAP-actin inhibition of INF2 suggests that HDAC6 might be required for cellular INF2 activation. Previously, we and others have shown that cell stimulation with ionomycin (IONO) or histamine causes an INF2-dependent cytosolic actin 'burst' 18, [31] [32] [33] . Here, we show that TubA pretreatment strongly reduces the IONO-and histamine-induced actin burst in U2OS cells (Fig. 5g,h) , and the downstream consequence of increased mitochondrial calcium 18 ( Fig. 5i,j) . These results show that HDAC6 can activate INF2 biochemically and in cells.
We also tested whether IONO treatment alters KAc-actin levels in U2OS cells. Western blotting of acetyl-lysine (Ac-K) from cell lysates resulted in high background noise. We took an alternative approach in which we expressed 2×strep-tagged CAP2, then affinity-purified the CAP2 and examined Ac-K levels of the bound actin at various time points after treatment. Mock treatment with DMSO results in measurable KAc-actin, and treatment with TubA strongly increases KAc-actin (Fig. 5k) . IONO treatment causes a significant drop in KAc-actin at 30 s, with a return to control levels at 2 min (Fig. 5k) . This time course correlates with that of the IONO-induced actin burst (Fig. 5g) . In addition, endogenous INF2 copurifies with CAP2 in DMSO-and TubA-treated samples, but copurification is greatly reduced at 30 s after IONO treatment (Fig. 5k) . These results suggest that IONO causes a transient decrease in lysine acetylation of actin, resulting in decreased INF2 binding.
Disease-associated INF2 mutants display reduced inhibition by CAP-actin.
Although multiple mutations in the INF2 DID are linked to FSGS and CMTD, the molecular mechanism of disease progression is unknown. We therefore investigated whether CAPactin could inhibit two INF2 mutants: R218Q, a common FSGS mutant 22 , and L77R, a CMTD mutant 23 . Arg 218 is located near the DAD-binding site but is not predicted to make direct contact with DAD 22 , whereas Leu 77 is localized on the opposite face of the DID from the DAD-binding site. CAP-CSKA displays reduced inhibition of both mutants biochemically, with R218Q being particularly resistant (Fig. 6a,b) , suggesting that disease-associated INF2 mutants are not efficiently regulated by CAP-KAc-actin.
We also tested the regulation of INF2-L77R and INF2-R218Q in cells, by transfecting mutant nonCAAX constructs into INF2-knockout (KO) U2OS cells. Fixed-cell analysis shows that both mutants display significantly higher cytosolic actin filaments than INF2-WT (Fig. 6c,d) . Live-cell analysis shows that cytoplasmic actin filament levels are significantly higher for both mutants than for the INF2-WT, and that IONO stimulation does not induce increased actin filaments in the mutants (Fig. 6e) . We also tested the interaction between INF2 mutants and CAP2 in cells, and found no apparent co-IP, in contrast to INF2-WT (Fig. 6f ). Finally, we tested the effect of TubA treatment on cytoplasmic actin filament levels in L77R-INF2-or R218Q-INF2-expressing cells, and found no decrease in these levels, suggesting that increased lysine acetylation of actin does not inhibit these mutants efficiently ( Supplementary  Fig. 5j,k) . These results show that two disease-associated INF2 mutants are poorly regulated in cells.
Discussion
Here we reveal a cellular role for KAc-actin, inhibition of INF2 through a KAc-actin-CAP complex. We refer to the mechanism as facilitated autoinhibition because an additional molecule is required to mediate the autoinhibitory interaction of INF2. Actin deacetylation through HDAC6 relieves INF2 inhibition, whereas cellular HDAC6 inhibition blocks stimulus-induced INF2 activation. Conversely, INF2 mutants linked to two human diseases, FSGS and CMTD, are poorly inhibited by CAP-KAc-actin and are constitutively active in cells.
A variety of actin PTMs have previously been identified 34 . Actin acetylation research has mainly focused on the N terminus, where all actins are modified 35 . Lysine acetylation of actin has been identified 34 but its importance has been unclear. Our demonstration that KAcactin inhibits INF2 adds to known acetylation events for other cytoskeletal proteins. Two actin-binding proteins have been shown to be acetylated: cortactin 36 and the formin mDia2 37 . In both cases, acetylation inhibits interaction with actin. Interestingly, formin proteins can influence tubulin acetylation through a variety of mechanisms 15, 38, 39 . The presence of CAP in the INF2 inhibitory complex is intriguing. CAP was originally identified in budding yeast as an interacting protein for adenylyl cyclase 40, 41 , but this interaction is not conserved in mammals. CAP binds both actin monomers and filaments [42] [43] [44] [45] . Purified CAP stimulates actin filament disassembly in the presence of cofilin or twinfilin, but CAP alone has little effect on actin disassembly 27, 46 . The two mammalian CAPs, CAP1 and CAP2, are approximately 60% identical and are differentially expressed 47, 48 . We show that both CAP1 and CAP2 inhibit INF2, and that CAP-actin directly interacts with INF2.
CAP-actin is a high-molecular-mass complex, consistent with previous reports of CAP hexamerization 26, 27 . Interestingly, additional INF2-inhibitory fractions from mouse brain tissue also contain CAP1 or CAP2. Gel-filtration profiles of these fractions suggest that cellular CAP is heterogeneous, and might include some non-hexameric species. Alternatively, CAP might associate with additional proteins. CAP can interact with several actin-binding proteins, including cofilin, profilin, twinfilin and ABP1 (refs. 27, 46, 49 ). Our purified BIF fraction contains several coeluting proteins, including subunits of vacuolar ATPase and exportin. These proteins might confer other properties.
Autoinhibition through the DID-DAD interaction is a major regulatory mechanism for most metazoan formins [3] [4] [5] . However, some formins that do not contain canonical DID or DAD are still subject to direct autoinhibition through N-and C-terminal interactions 50 . Other formins are regulated by protein binding in trans [51] [52] [53] [54] [55] [56] [57] . Our results demonstrate the facilitation of formin autoinhibition by another protein. The fact that a mutation known to disrupt the interaction between DID and DAD results in constitutive INF2 activity ( Supplementary Fig. 1 ) suggests that the interaction between DID and DAD is required. However, we cannot rule out the possibility that CAP-actin serves as a bridge between DID and DAD, with DAD binding to KAc-actin directly 11, 24 . The fact that CAP can associate with INF2 suggests that CAP is part of the inhibitory complex and not merely delivering KAc-actin. Our schematic model of an inhibitory complex between CAP-actin and INF2 (Fig. 6g) does not distinguish between direct DID-DAD interaction or the CAP-actin bridge model, nor does it depict CAP hexamerization; these are two issues to be addressed in future work.
The acetylation positions identified on actin provide insight into the inhibitory mechanism of the CAP-KAc-actin complex. Four lysines display acetylation increases in the inhibitory CAP-actin complex: Lys 50, Lys 68, Lys 215 and Lys 315. These residues are all on the surface of the actin monomer ( Supplementary Fig. 6a ), although Lys 315 probably contributes to interactions between subdomains. These residues do not make significant intersubunit contacts in the filament (Supplementary Fig. 6b ), so acetylation may not disrupt polymerization. One acetylation site, Lys 68, might alter the binding affinity of CAP, as it is located at the binding interface in the dimeric structure of the CARP domain of CAP with actin 58 ( Supplementary Fig. 6c ). Current structural models of the formin homology 2 domain bound to actin suggest that there is little interaction between these residues and the FH2 (Supplementary Fig. 6d ).
Several questions arise regarding cellular INF2 regulation through this mechanism. First, what percentage of actin must be acetylated? We have previously determined total cytosolic actin to be approximately 200 μM in U2OS cells 59 , consistent with values in other cell types 28 , whereas INF2 levels are likely to be less than 1 μM. Therefore, acetylation of less than 1% of cytosolic actin could suffice for INF2 inhibition.
A second question concerns the cellular signal that triggers actin deacetylation and INF2 activation. It is clear that increased cytoplasmic calcium activates INF2 (refs. 18, [31] [32] [33] ), but the link to decreased actin acetylation is unclear. One possible link is through calciummediated metabolic changes 60 . Lysine acetylation is governed by the balance between lysine acetyltransferase (KAT) and deacetylase activities, and the appreciable cellular acetylation-deacetylation flux 30 could be due changes in either process. Several cytosolic members of the approximately 20 member mammalian KAT family could mediate actin acetylation 30 . An intriguing possibility is that fluctuating levels of the acetyl donor, acetyl-CoA, could regulate KAT activity 61 , perhaps relating to the role of INF2 in mitochondrial division 18, 19 and the relationship between mitochondrial division and metabolism 62 . Alternatively, increased calcium might increase deacetylase activity, with HDAC6 being a prime candidate. Interestingly, HDAC6 activity has been shown to cause an increase in cellular actin polymerization 36, 63 . In addition, calmodulin might participate in calcium-mediated INF2 activation. An interaction between INF2 and calcium-bound calmodulin has been shown in cell lysates . Additional values at 48 μM INF2-Nterm, which are not present in the graph but are accounted for in the fit curves, are 217 for −CAP-293A-T and 211 for +CAP-293A-T. The experiment was conducted once. g, IONO-induced changes in actin filaments in U2OS cells that were pretreated with either DMSO or 50 µM TubA. Data are mean ± s.e.m.; n = 40, 38 and 48 independent cells for DMSO, IONO and IONO and TubA, respectively. h, Histamine-induced changes on actin filaments in U2OS cells that were pretreated with either DMSO or 50 µM TubA. Data are mean ± s.e.m.; n = 15 independent cells for both conditions. i, IONO-induced changes on mitochondrial calcium levels in U2OS cells that were pretreated with either DMSO or 50 µM TubA. Data are mean ± s.e.m.; n = 29, 28 and 22 independent cells for DMSO, IONO, and IONO and TubA, respectively. j, Histamine-induced changes on mitochondrial calcium in U2OS cells that were pretreated with either DMSO or 50 µM TubA. Data are mean ± s.e.m.; n = 15 independent cells for both conditions. Arrows in g-j indicate the addition of IONO or histamine, as indicated. k, Strep-Tactin pull-downs performed using cell lysates of U2OS cells that were overexpressing CAP2-GFP-2×strep. Cells were treated identically before lysis. CAP2-GFP was isolated, and CAP2-bound actin and probed by western blotting using anti-actin and anti-Ac-Lys antibodies. The experiment was conducted once.
to DID, but few are located in the DAD-binding site, suggesting that they do not affect this interaction directly. Furthermore, all disease-associated mutations are dominant, and expression of select mutants causes aberrant cellular actin polymerization 22 , suggesting that both diseases are due to increased INF2 activity. We show that two disease-associated mutants are poorly inhibited by CAP-KAcactin, suggesting that this interaction is affected. Interestingly, recent studies show that aberrant HDAC6 activity can lead to CMTD [64] [65] [66] . Our study provides a framework for understanding both actin regulation and disease progression in a different way.
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Methods
Plasmids. Human INF2-FL-nonCAAX cDNA was produced from a human INF2-CAAX clone (Origene SC313010, NM_022489) in which the CAAX exon was replaced with the nonCAAX exon, a 12-base deletion in the purchased clone was corrected, and codon optimization was carried out. This construct was subsequently cloned into the EcoRI and XhoI sites of a modified eGFP-C1 vector (Clontech) containing Strep-tag II (IBA Life Sciences) and an HRV3C cleavage site that was located N-terminal to the INF2 start codon. INF2 mutations (A149D, L77R and R218Q) were generated in the above-mentioned INF2-FL-nonCAAX construct by site-directed mutagenesis. Human CAP1 and CAP2 cDNAs were purchased from NovoPro (710829-5 (NM-006367) and 710470-11 (NM-006366)), then the entire open reading frame was PCR-amplified and cloned into a modified eGFP-N1 vector (Clonetech)-containing an HRV3C cleavage site followed by the GFP open reading frame, followed by Strep-tag II-using XhoI and KpnI sites. The Flag-tagged human HDAC6 plasmid was purchased from Addgene (30482). Mito-R-GECO1 (K d = 0.48 µM for calcium) construct, as well as GFP-F-tractin and mApple-F-tractin constructs have been described previously 18 . For strep-tagged protein purification from FreeStyle 293 cells, all of the following steps were performed either at 4 °C or on ice. Cells were pelleted at 300g for 15 min, and the pellets were resuspended in 45 ml EB-S (100 mM HEPES buffer pH 7.4, 500 mM NaCl 2 , 5 mM EDTA, 1 mM dithiothreitol (DTT), 1% v/v Triton X-100, 2 μg ml −1 leupeptin, 10 μg ml −1 aprotinin, 2 μg ml −1 pepstatin A, 1 μg ml
Recombinant
calpeptin, 1 μg ml −1 calpain inhibitor I, 1 mM bezamidine and 1:1,000 dilution of universal nuclease (Thermo Fisher, 88702)) per 5 ml cell pellet. followed by 30 min end-over-end mixing at 4 °C. For TubA-treated cells, EB-S also contained 500 nM tricostatin A (Selleckchem, S1045) and 10 mM sodium butyrate (Sigma-Aldrich, 303410). The cell debris was removed by ultracentrifugation at 185,000g for 1 h (Ti45 rotor, Beckman), and the supernatant was blocked with avidin (20 μg ml −1 ; Sigma-Aldrich, 189725) then applied to Strep-Tactin Superflow resin (2-1206-025; IBA) equilibrated in EB-S. After a thorough wash with WB (10 mM HEPES pH 7.4, 150 mM NaCl 2 , 1 mM EDTA and 1 mM DTT), the column was either (1) treated with HRV3C protease in WB (at 1:50 enzyme to substrate molar ratio) for 16 h at 4 °C followed by a three-column volume WB wash to obtain untagged protein or (2) eluted with strep elution buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT and 2.5 mM desthiobiotin) to obtain the strep-GFP fusion protein. The protein was concentrated using a 30,000 MWCO Amicon Ultra-15 filter unit (Millipore) before further purification through a Superdex 200 16/60 gel-filtration column (GE Bioscience) equilibrated with 10 mM HEPES pH 7.4, 50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA and 1 mM DTT. The protein was further concentrated to >10 µM before being aliquoted, frozen in liquid nitrogen and stored at −80 °C. In all cases, HEPES pH given is at 23 °C.
For the purification of Flag-tagged protein from Freestyle 293 cells, cells were collected in the same way as described above, and lysed in EB-F (50 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% v/v Triton X-100, 2 μg ml −1 leupeptin, 10 μg ml −1 aprotinin, 2 μg ml −1 pepstatin A, 1 μg ml −1 calpeptin, 1 μg ml
calpain inhibitor I, 1 mM bezamidine and 1:1,000 dilution of universal nuclease). Cell lysate was clarified by ultracentrifugation at 185,000g for 1 h (Ti45), and the supernatant was loaded onto Anti-Flag M2 affinity gel (Sigma-Aldrich, A2220) equilibrated with EB-F. The column was washed with WB-F (10 mM HEPES pH 7.4, 50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA and 1 mM DTT) thoroughly, and Flag-tagged protein was eluted with Flag elution buffer (10 mM HEPES pH 7.4, 50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 1 mM DTT and 100 μg ml −1 Flag octapeptide (Sigma-Aldrich, F3290)). The protein was gel filtered on Superdex 200, concentrated and stored as described above.
Actin preparation. Details of the actin preparation have been described previously 16 . RSKA (fresh muscle; Fox and Crow Farm) or CSKA (frozen chicken breast; Trader Joe's) was purified from acetone powder. Rabbit muscle actin was labelled with pyrenyliodoacetamide, TAMRA NHS ester (Molecular Probes, C1171) or Oregon488 NHS ester (Thermo Fisher, O6185). Both labelled and unlabelled actin were gel-filtered on Superdex 75 (GE Biosciences) and stored in G-buffer (2 mM Tris-HCl buffer pH 8, 0.5 mM DTT, 0.2 mM ATP, 0.1 mM CaCl 2 and 0.01% w/v sodium azide) at 4 °C.
For mouse brain-tissue actin purification, all steps were conducted at 4 °C. Mouse brains (50 g) were homogenized using a polytron (Kinematica PT3100) in EB (50 mM HEPES pH 7.4, 1 mM MgCl 2 , 1 mM EGTA, 2 mM DTT, 2 μg ml −1 leupeptin, 10 μg ml −1 aprotinin, 2 μg ml −1 pepstatin A, 1 μg ml −1 calpeptin, 1 μg ml −1 calpain inhibitor I and 1 mM bezamidine). Cell debris was removed by ultracentrifugation at 185,000g (Ti45), and the supernatant was filtered through 0.45 μm filters. The supernatant was supplemented with ATP (4 mM), MgCl 2 (4 mM) and sodium phosphate (NaPO 4 , pH 7.0, 20 mM), and this was followed by end-over-end mixing at 4 °C for 16 h. Polymerized brain actin was pelleted by centrifugation for 3 h at 185,000g, and the pellet was washed by resuspensionpelleting cycle sequentially with 2× WB1 (500 mM KCl, 0.5% v/v Thesit, 10 mM NaPO 4 pH 7.0, 2 mM MgCl 2 , 2 mM ATP, 1 mM DTT and 2 μg ml −1 leupeptin), and 2× WB2 (50 mM KCl, 10 mM NaPO 4 pH 7.0, 2 mM MgCl 2 , 2 mM ATP, 1 mM DTT and 2 μg ml −1 leupeptin). The pellet was then washed with G-buffer with minimal disturbance and then resuspended in G-buffer before shearing through a 30G 1/2 needle. Sheared actin was dialysed in G-buffer for 16 h before ultracentrifugation at 185,000g (Ti70.1 rotor, Beckman), then the concentration was made up to >10 μM.
Purification of BIF. Purification of BIF was conducted at 4 °C. Mouse brains (100 g; Pel-Freez Biologicals) were homogenized with a polytron in EB. Cell debris was removed by ultracentrifugation at 185,000g (Ti45 rotor), and the supernatant was filtered through 0.45 μm filters then supplemented with KCl to 100 mM before loading onto a 90 ml Q-Sepharose column (GE Biosciences). The BIF-containing fraction was eluted with Q350 (350 mM KCl, 50 mM HEPES pH 7.4, 1 mM MgCl 2 , 5 mM EGTA, 1 mM DTT, 2 μg ml −1 leupeptin, 10 μg ml −1 aprotinin, 2 μg ml
pepstatin A, 1 μg ml −1 calpeptin and 1 μg ml −1 calpain inhibitor I). The eluate was diluted threefold with EB before loading onto a 50 ml Source Q column (GE Biosciences). Linear ionic strength gradient elution was performed using Q100 (100 mM KCl, 10 mM HEPES pH 7.4, 1 mM MgCl 2 , 1 mM EGTA and 1 mM DTT) and Q350 (Q100 + 250 mM KCl). Fractions were dialysed into 1.5× KMEH + DTT (15 mM HEPES pH 7.4, 75 mM KCl, 1.5 mM MgCl 2 , 1.5 mM EGTA and 1 mM DTT) and tested for inhibition of INF2-FL activity by pyrene-actin polymerization assay (20 nM INF2, 2 μM actin (5% pyrene)). Inhibitory peak fractions were pooled and passed over a Superdex 200 16/60 gel filtration column equilibrated in 1.5× KMEH + DTT. Inhibitory peak fractions were pooled and purified through an 8 ml Source Q column (GE Biosciences) at pH 8.8 with a gradient ranging from 100 to 300 mM KCl (in 10 mM Tris pH 8.8, 1 mM MgCl 2 , 1 mM EGTA and 1 mM DTT). Fractions were dialysed into 1.5× KMEH + DTT and assayed. Peak inhibitory fractions were pooled and dialysed into Q0 (10 mM HEPES pH 6.8 at 4 °C, 1 mM MgCl 2 , 1 mM EGTA and 1 mM DTT) before they were applied to a 1 ml SourceS column (GE Biosciences) with gradient elution from 0 to 100 mM KCl (in 10 mM HEPES pH 6.8 at 4 °C, 1 mM MgCl 2 , 1 mM EGTA and 1 mM DTT). Fractions were dialysed into 1.5× KMEH + DTT, assayed for inhibitory activity, analysed by silverstained SDS-PAGE and pooled.
To determine the concentration of CAP in BIF, samples from Source S column fractions (Fig. 1i) were resolved-along with actin standards with known mass-by 7.5% SDS-PAGE. Gels were stained using colloidal Coomassie stain (Thermo Fisher), and the CAP concentration was analysed by densitometry (ImageJ), using actin as a standard. For determination of IC 50 for CAP in BIF, a linear fit was applied to the activity of BIF in Fig. 2f , and the activity of actin was used as baseline. TIRF microscopy. Detailed methods for the TIRF microscopy have been described elsewhere 17 . In brief, glass flow chambers were assembled using micro cover glasses (22 × 22 and 18 × 18 mm, No. 1.5; VWR) with double-stick adhesive tape to hold 10 μl volume. Before assembly, cover glasses were washed in acetone (50 min), ethanol (10 min) and MilliQ water (1 min), then incubated in 1:2 ratio of 30% H 2 O 2 :H 2 SO 4 for 1 h. Cover glasses were then rinsed with water, followed by 0.1 M KOH, followed by water again and dried with inert gas before silanization overnight in 0.0025% dichlorodimethyl silane (Sigma-Aldrich, 85126) and chloroform. Subsequently, the cover glasses were washed with methanol, dried with inert gas and stored in clean, sealed containers. Chambers were incubated with 1% w/v Pluronic F127 (Sigma-Aldrich, P2443) in BRB80 (80 mM PIPES/KOH pH 6.9, 1 mM EGTA and 1 mM MgCl 2 ) for 1 min and then equilibrated in TIRF buffer (10 mM imidazole pH 7, 50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 1 mM DTT, 100 mM DTT, 0.2 mM ATP, 15 mM glucose, 0.5% methylcellulose, 0.01 mg ml −1 catalase (Sigma-Aldrich, C3515), 0.05 mg ml −1 glucose oxidase (Sigma-Aldrich, G6125) and 0.1% BSA). Nucleation-elongation assays were conducted as previously described 16 . In brief, unlabelled RSKA monomers were mixed with 20% TAMRA or Oregon-labelled actin monomers (2 μM) in G-buffer, diluted with profilin (3 μM) in 2× TIRF buffer in the presence or absence of 1 nM untagged INF2-FL and/or 100 nM CAP-CKSA, and introduced into the flow chamber. The filaments were visualized on a Nikon Eclipse Ti-E inverted microscope-with 488-or 561-nm lasers-that was driven by Nikon Elements software. Single-colour images were acquired every 5 s at 100 ms exposure using a TIRF objective (×60/1.49 NA) and an electron-multiplying charge-coupled device camera (Andor) with an Andor TuCam adapter using Perfect Focus. Filament number and length were measured manually from frame to frame using Nikon NIS-Elements 4.40.00. For display of TIRF images, original images were adjusted using Photoshop CS5 (Adobe Inc.). Curve function was used to lock the intensity of the filaments and then reduce the background haze. All panels were adjusted as a single image.
Pyrene-actin polymerization assay. RSKA in G-buffer (6 μM actin, 5% pyrene) was converted to Mg 2+ salt by the addition of 1 mM EGTA and 0.1 mM Immunodepletion. The initial SourceQ inhibitory fraction pool from mouse brain preparations (fractions 38-40, Supplementary Fig. 2a ) was incubated with antibodies against vacuolar ATPase subunit A, vacuolar ATPase subunit B2, heatshock cognate 71 kDa protein and CAP2 or with control IgG (rabbit anti-GFP), at 4 °C. In brief, 10 μl of each antibody was added into 500 μl fractions, and this was followed by 16 h incubation with end-over-end mixing at 4 °C. The antigenantibody complex was precipitated by protein A or protein G agarose beads (GE Biosciences). The supernatant was recovered and tested for INF2 inhibition. Supernatants and pellets were probed for the depleted protein.
CAP-bound actin exchange assay. CAP2-GFP-2×strep protein purified from 293 cells (also containing bound actin) was immobilized on Strep-Tactin beads, then washed with G-buffer. The indicated species of actin (in G-buffer) was incubated with CAP2-GFP Strep-Tactin beads at 4 °C with end-over-end mixing for 12 h. The concentrations of added actin and bead-bound CAP2-GFP in exchange reactions were 5 μM and 1 μM, respectively. Beads were washed with 20 volumes of G-buffer. Exchanged CAP2-GFP was removed from beads by either by eluting with G-buffer containing 2.5 mM dethiobiotin or by cleavage from beads by HRV3C protease (1:50, overnight at 4 °C).
Protein-binding assays. For the Strep-Tactin pull-down of purified proteins, 1 μM Strep-GFP-tagged protein (GFP, INF2-FL or INF2-FFC) was incubated with 2 μM untagged CAP (with or without actin exchange) in IPB (50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 10 mM HEPES pH 7.4, 1 mM DTT and 1% v/v Thesit) with end-overend mixing at 4 °C for 8 h. Separately, 0.2 volumes of 50% Strep-Tactin Superflow bead slurry were blocked with 10 mg ml −1 avidin and washed in 50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 10 mM HEPES, pH 7.4, and 1 mM DTT before addition to the protein mix. After 8 h incubation at 4 °C, beads were washed with IPB (now containing 0.2% v/v Thesit). The bead pellet was probed by western blotting with anti-GFP, anti-CAP2 or anti-actin antibodies.
For the Strep-Tactin pull-down from cell extracts, WT U2OS cells expressing CAP2-GFP were treated with 50 μM TubA for 1 h, DMSO for 15 min or 4 μM IONO (in serum-containing medium) for the indicated length of time before lysis in prechilled PDEB (50 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 10 mM HEPES pH 7.4, 1 mM DTT, 3% v/v Thesit, 2 μg ml −1 leupeptin, 10 μg ml −1 aprotinin, 2 μg ml −1 pepstatin A, 1 μg ml −1 calpeptin, 1 μg ml −1 calpain inhibitor I, 1 mM bezamidine, 500 nM tricostatin A and 10 mM sodium butyrate) in the dish (immediately after removal of medium) and then incubated with shaking at 4 °C for 15 min. Lysate was centrifuged at 100,000 r.p.m. in a TLA120 rotor (Beckman) at 4 °C for 20 min, and the supernatant was blocked with avidin (20 μg ml ; SigmaAldrich, 189725) then mixed with Strep-Tactin Superflow resin (prewashed with PDEB) with end-over-end mixing for 3 h at 4 °C. Beads were washed with PDEB twice and 1× PBS buffer twice. The pellet was resolved by SDS-PAGE, and western blot probed with anti-actin, anti-acetyl-lysine or anti-INF2 antibodies.
For the IP of purified proteins, 0.5 μM Strep-GFP-tagged protein (GFP-INF2-FL or GFP-INF2-FFC) was incubated with 2 μM untagged CAP (with or without exchange) in IPB for 3 h at 4 °C. Then, 50 μg anti-GFP antibody was added and incubated for 12 h with end-over-end mixing at 4 °C. Protein A beads were blocked with 10 mg ml −1 avidin and washed in IPB before incubating with protein mix for 3 h. Beads were washed with IPB (now containing 0.2% v/v Thesit). The bead pellet was resolved by SDS-PAGE, and the western blot was probed with anti-GFP, anti-CAP2 or anti-actin antibodies. For statistical analysis, results from three independent experiments were quantified. CAP2 band intensity was normalized against a GFP control using ImageJ.
For immunoprecipitation from cell extracts, INF2-KO U2OS cells expressing GFP, GFP-INF2-FL-nonCAAX-WT, GFP-INF2FFC or GFP-INF2-FL-nonCAAX-A149D, GFP-INF2-FL-nonCAAX-L77R and GFP-INF2-FL-nonCAAX-R218Q mutants were trypsinized and centrifuged at 300g for 5 min, and the cell pellet washed with PBS. The cell pellet was lysed with prechilled IPEB (50 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 10 mM HEPES pH 7.4, 1 mM DTT, 3% v/v Thesit, 2 μg ml −1 leupeptin, 10 μg ml −1 aprotinin, 2 μg ml −1 pepstatin A, 1 μg ml −1 calpeptin, 1 μg ml −1 calpain inhibitor I and 1 mM bezamidine), then treated with latrunculin A (Sigma-Aldrich, L5163) at 20 μM for 15 min on ice. Cell debris was removed by ultracentrifugation at 100,000 r.p.m. (TLA-100 rotor) . The supernatant was incubated with 10 μg anti-GFP with end-over-end mixing at 4 °C for 12 h. Protein A beads (20 μl) were pre-blocked with 10 mg ml −1 avidin and washed in IPEB before incubating with lysate for 3 h. Beads were washed with IPW (50 mM KCl, 1 mM MgCl 2 , 1 mM EGTA, 10 mM HEPES pH 7.4, 1 mM DTT and 0.2% v/v Thesit), and bound proteins were resolved by SDS-PAGE western blot and probed with anti-GFP and anti-CAP2 antibodies.
Fluorescence polarization anisotropy measurements conducted using INF2-Cterm (amino acids 941-1249 of INF2-CAAX, expressed in bacteria) labelled with TMR, as previously described 24 . TMR-INF2-Cterm (100 nM) was mixed with CAP-293A-T and/or INF2-Nterm (amino acids 1-420, expressed in bacteria as described previously 24 ) in 50 mM KCl, 1 mM MgCl 2 , 5 mM EGTA, 10 mM HEPES pH 7.4 and 1 mM DTT at 23 °C, and fluorescence anisotropy was measured using a Tecan M1000 plate reader. The concentration of CAP-293A-T was held constant at 20 M in some assays. Binding curves were fitted using standard hyperbolic saturation fitting 67 . In the case of the INF2-Cterm-INF2-Nterm interaction in the absence of CAP-293A-T, saturation was not obtained and had to be assumed on the basis of extrapolation of the curve, which adds uncertainty to the K d app value of 28 μM. For this reason, we state that CAP-293A-T increases the affinity of INF2-Nterm for INF2-Cterm at least fivefold, which is a conservative estimate of this increase.
Mass spectrometry. Samples were separated by SDS-PAGE and bands were excised, destained and digested with trypsin in 50 mM ammonium bicarbonate overnight at 37 °C. Peptides were extracted using 5% formic acid and 50% acetonitrile, and dried. Peptides were analysed on a Fusion Orbitrap mass spectrometer (Thermo Scientific) that was equipped with an Easy-nLC 1000 (Thermo Scientific). Raw data were searched using COMET in high-resolution mode 68 , trypsin enzyme specificity with up to three missed cleavages, and carbamidomethylcysteine as a fixed modification. Oxidized methionine and acetylated lysine were searched as variable modifications. Quantification of spectra obtained from liquid chromatography and tandem mass spectrometry was performed using MassChroQ 69 . Peptides were corrected for on the basis of protein amount, ratios of CAP and TubA in DMSO were calculated on a per-charge-state and per-peptide basis, and averaged. Additional analyses were performed at the Taplin Mass Spectrometry Facility, Harvard.
Live-cell imaging. Wild-type human osteosarcoma U2OS cells (American Type Culture Collection, HTB96) or INF2-KO U2OS cells 18 were grown in DMEM (Invitrogen) supplemented with 10% calf serum (Atlanta Biologicals). Cells were tested every 6 months for mycoplasma contamination using the LookOut PCR detection kit (Sigma-Aldrich). Cells were seeded at 4 × 10 5 cells per well in a six-well dish approximately 16 h before transfection. Plasmid transfections were performed in OPTI-MEM medium (Invitrogen) with 2 μl Lipofectamine 2000 (Invitrogen) and 500 ng GFP-F-tractin and/or mito-R-GECO1, or GFP-INF2-FL-nonCAAX, GFP-INF2-FL-nonCAAX-L77R mutant or GFP-INF2-FLnonCAAX-R218Q mutant with mApple-F-tractin per well for 6 h, followed by trypsinization and replating onto glass bottom MatTek dishes (P35G-1.5-14-C) at ~2 × 10 5 cells per well. Cells were imaged live in DMEM (GIBCO, 21063-029) that was supplemented with 10% neonatal calf serum (HyClone, SH30118.03) around 16-24 h after transfection. For histamine or IONO treatments, 100 µM histamine (Sigma-Aldrich, H7125; from 100 mM stock in DMSO), 4 µM IONO (Sigma-Aldrich, I0634; from 2 mM stock in DMSO) or DMSO alone was added at 1 min after commencement of imaging, and imaging continued for 5-10 min. The medium was pre-equilibrated for temperature and CO 2 content before use. For TubA treatments, cells were pretreated with either 50 µM TubA (from 10 mM stock in DMSO) or equal volume DMSO (control) for 60 min before addition of histamine or IONO. Note that TubA-containing medium was made immediately before its addition to the cells, and individually for each plate. Imaging was conducted on a Dragonfly 302 spinning disk confocal (Andor Technology Inc.) on a Nikon Ti-E base and equipped with an iXon Ultra 888 EMCCD camera and a Tokai Hit stage-top incubator. Lasers used were as follows: solid-state 405 smart diode 100 mW, solid-state 488 OPSL smart laser 50 mW, solid-state 560 OPSL smart laser 50 mW and solid-state 637 OPSL smart laser 140 mW. The objective used was a ×100/1.4 NA CFI Plan Apo (Nikon). Images were acquired using Fusion software (Andor); imaging was conducted in a medial region of the cell, approximately 2 μm above the basal surface. w/v 4,6-diamidino-2-phenylindole (DAPI; Calbiochem, 268298) for 10 min at 23 °C in the dark followed by a PBS wash. Cells were imaged in PBS using the Andor Dragonfly microscope and Zyla 4.2 Mpixel sCMOS camera. z-stacks with 0.2 μm step size were acquired. Images from middle three z planes were used for quantification. Cells were selected on the basis of GFP expression and were then imaged for both GFP and phalloidin staining without first examining the degree of phalloidin staining.
Measurements of actin intensity in fixed cells, and calcium changes and actin burst in live cells. TRITC-phalloidin intensity of two regions of interest (ROIs) in the perinuclear region was taken per cell, and was normalized to the intensity of two ROIs taken from a nuclear region (which lack measurable phalloidin staining).
Measurements of mitochondrial calcium and actin burst in live cells were conducted as described previously 18 . Mean fluorescence was calculated for each cell using ImageJ (NIH). Fluorescence values for each time point after drug treatment (F) were normalized to the average initial fluorescence (first five or six frames before stimulation (F 0 )) and plotted against time as F/F 0 . For calcium measurements, all cells in the imaging field were analysed. Where cells were closely juxtaposed, calcium changes were analysed in the same ROI. For actin burst measurements, mean fluorescence values for each time point were calculated from four cells per ROI that were selected in the perinuclear region using ImageJ. Only cells fully in the imaging field were analysed. Cells were excluded from analysis for the following reasons: they were rounded up, or a substantial concentration of basal stress fibre signal in the field contributed to an abnormally high initial signal. Excluded cell percentages were as follows, in Fig. 5g : 15%, 16% and 19% for DMSO, +IONO and +TubA +IONO, respectively; and in Fig. 5h : 32% for DMSO and histamine, and TubA and histamine.
Statistical analysis and reproducibility. Errors (s.e.m.) were calculated using Excel (Microsoft, v.16.16.1). Comparisons by one-sided Student's t-test (paired) were conducted using GraphPad. Most experiments were reproduced three or more times (as described in the figure legends) with similar results. One exception was the BIF-purification procedure that was performed in full only once. All purification steps, however, were optimized in small-scale pilot experiments, typically two or three for each chromatographic column. Purified brain actin was tested for INF2 inhibition only once.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
The mass-spectrometry proteomics data (Supplementary Tables 1, 2 All studies must disclose on these points even when the disclosure is negative.
Sample size
No statistical methods were used to predetermine sample size.
Data exclusions For pyrene-actin polymerization assays, curves were excluded if they contained sudden increases or decreases in fluorescence signal due to electronic fluctuations (ie. substantial signal changes occurring from one time point to another). For live-cell microscopy data, cells were excluded from analysis if they were not fully in the imaging field, if they rounded up significantly during the time course, or if (for actin) significant stress fibers were present in the confocal section. For fixed cell analysis, all imaged cells were analyzed. These exclusion criteria were pre-established.
Replication
The cellular data were replicated on multiple independent coverslips, with individual transfections (where transfections were used). Biochemical data were repeated through optimization (BIF purification), multiple replicates in individual experiments, or separate experiments conducted on separate days. All attempts at replication were successful, with the exception of the tubastatin A cellular treatments. These were initially inconsistent, but the reason for the inconsistency was determined to be the length of time the tubastatin A was in the cell culture medium prior to adding to the cells. Once we determined the reason for the inconsistency, we adopted the procedure of adding tubastatin A to the culture medium immediately prior to addition to the cells (within 2 min), which made the effects of tubastatin A reproducible.
Randomization Data were not randomized prior to analysis. For fixed cell imaging and analysis of TRITC-phalloidin staining, cells were selected based on GFP expression, then images were collected for both GFP and TRITC without first examining quality of TRITC signal. All imaged cells were subsequently analyzed. For live-cell analysis, cells were selected that were well spread and contained the fluorescent proteins to be analyzed (mitochondrial calcium or cytoplasmic Ftractin), then movies acquired during treatment with the indicated compounds. Some cells were excluded from subsequent analysis based on the criteria outlined above.
Blinding
The investigator was not blinded prior to analysis, except for the cellular assays in Figure S5k . Blinding is not common practice for the biochemical studies conducted.
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